Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who fail prior NS5A containing DAA regimens: Results of the GS-US-342-1553 study

The requested reference [a69904ae726f6819ffe0d5cee51ce5e92e4068de] no longer exists in our database. It has been replaced by the current reference: [61d3bcdd476f4b8bb71ca9c21738b0f937975245]

Authors
Category Primary study
ConferenceHepatology International
Year 2017
This article has no abstract
Epistemonikos ID: 0aca18e891078c472db743345bfcfe4477e5c7be
First added on: Apr 29, 2026